UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view

UroGen Pharma Ltd.

JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).
Net loss $23.7M ($0.55/share) vs $21.9M ($0.68/share) in Q3 2023.
NDA for UGN-102 accepted; PDUFA target action date June 13, 2025.
Full-year 2024 JELMYTO revenue expected below prior guidance low end; still low double-digit YoY growth.
Cash, equivalents, marketable securities $254.2M as of Sept 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.